Table 5.

Recommended Surveillance for Individuals with Perrault Syndrome

System/Concern Evaluation Frequency
Hearing
  • Routine audiologic assessment for possible progressive hearing impairment
  • Audiologic surveillance not required for persons w/profound hearing loss
Annually
Musculoskeletal Assess bone density in women on maintenance estrogen replacement therapy.Every ~5 yrs
Endocrine
  • Before puberty: clinical staging of puberty
  • During induction of puberty: adjustment of estrogen dose
Every 3 mos
Women on maintenance estrogen replacement therapy: assessment of withdrawal bleeding & well beingAnnually

From: Perrault Syndrome

Cover of GeneReviews®
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2024.
Copyright © 1993-2024, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2024 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.